Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cTACE vs DEBTACE and impact on tumour mutation burden in unresectable primary liver cancer
ChiCTR2100042773Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Feb 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pirarubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Tumour mutation burden (TMB), Disease control rate (DCR) and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
pirarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100042773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042773.